Related Experiment Videos

Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes

S Sriskandan1, A McKee, L Hall

  • 1Department of Infectious Diseases, Royal Postgraduate Medical School, London, UK.

Insights

Sub-inhibitory ampicillin increased Streptococcus pyogenes toxin production more than clindamycin. Clindamycin is recommended for treating streptococcal toxic shock-like syndrome to reduce superantigen synthesis.

Area of Science:

  • Microbiology
  • Toxicology
  • Pharmacology

Background:

  • Streptococcus pyogenes can cause severe infections like streptococcal toxic shock-like syndrome (STSS).
  • Superantigens, such as streptococcal pyrogenic exotoxin A (SPEA), play a key role in STSS pathogenesis.
  • Sub-inhibitory antibiotic concentrations may affect bacterial toxin production.

Purpose of the Study:

  • To investigate the effect of sub-inhibitory ampicillin and clindamycin on SPEA production and superantigenic activity in Streptococcus pyogenes.
  • To determine the optimal antibiotic choice for managing STSS by assessing their impact on superantigen synthesis.

Main Methods:

  • Streptococcus pyogenes cultures were treated with sub-inhibitory concentrations of ampicillin and clindamycin.
  • Streptococcal pyrogenic exotoxin A (SPEA) production was quantified after 6 hours of incubation.
  • Superantigenic (promitogenic) activity of bacterial supernatants was measured.

Main Results:

  • SPEA production was higher in ampicillin-treated cultures compared to clindamycin-treated cultures, though not statistically significant (P=0.25).
  • Superantigenic activity was significantly higher in ampicillin-treated cultures (P=0.0001) than in clindamycin-treated cultures.
  • Clindamycin significantly inhibited both SPEA production and superantigenic activity.

Conclusions:

  • Clindamycin demonstrates a greater inhibitory effect on Streptococcus pyogenes superantigen synthesis compared to ampicillin at sub-inhibitory concentrations.
  • These findings support the use of clindamycin as a preferred therapeutic agent for streptococcal toxic shock-like syndrome to mitigate toxin-mediated pathology.

Related Concept Videos